190 related articles for article (PubMed ID: 31445231)
1. Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
Du Q; Feng X; Wang Y; Xu X; Zhang Y; Qu X; Li Z; Bian J
Eur J Med Chem; 2019 Nov; 182():111629. PubMed ID: 31445231
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
Liu C; Nan Y; Xia Z; Gu K; Chen C; Dong X; Ju D; Zhao W
Bioorg Med Chem Lett; 2020 Apr; 30(8):127038. PubMed ID: 32088128
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO.
Feng X; Shen P; Wang Y; Li Z; Bian J
Biochem Pharmacol; 2019 Oct; 168():214-223. PubMed ID: 31306643
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Chen S; Guo W; Liu X; Sun P; Wang Y; Ding C; Meng L; Zhang A
Eur J Med Chem; 2019 Oct; 179():38-55. PubMed ID: 31233921
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
Cui G; Lai F; Wang X; Chen X; Xu B
Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
[TBL] [Abstract][Full Text] [Related]
7. Discovery of IDO1 and DNA dual targeting antitumor agents.
Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
Org Biomol Chem; 2017 Dec; 15(47):9992-9995. PubMed ID: 29177308
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
[TBL] [Abstract][Full Text] [Related]
11. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X
Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.
Ye K; Wang K; Wang T; Tang H; Wang L; Zhang W; Jiang S; Zhang X; Zhang K
Eur J Med Chem; 2023 Mar; 250():115217. PubMed ID: 36842272
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of flavonoids isolated from
Kwon M; Ko SK; Jang M; Kim GH; Ryoo IJ; Son S; Ryu HW; Oh SR; Lee WK; Kim BY; Jang JH; Ahn JS
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1481-1488. PubMed ID: 31423846
[TBL] [Abstract][Full Text] [Related]
15. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.
Coluccia A; Passacantilli S; Famiglini V; Sabatino M; Patsilinakos A; Ragno R; Mazzoccoli C; Sisinni L; Okuno A; Takikawa O; Silvestri R; La Regina G
J Med Chem; 2016 Nov; 59(21):9760-9773. PubMed ID: 27690429
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
[TBL] [Abstract][Full Text] [Related]
19. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
[TBL] [Abstract][Full Text] [Related]
20.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
